Law360, New York (April 22, 2010, 5:32 PM ET) -- A federal judge signed off Thursday on the dismissal of claims between plaintiffs Celgene Corp. and Novartis Pharmaceuticals Corp. and defendant Actavis South Atlantic LLC in a patent infringement suit over attention deficit hyperactivity disorder drug Focalin XR.
Judge Freda L. Wolfson of the U.S. District Court for the District of New Jersey dismissed all the claims in the case, on the heels of a March filing by the parties that stayed the case pending review of a settlement agreement.
The settlement came at the outset...
Focalin IP Deal Between Celgene, Actavis Wins OK
To view the full article, take a free trial now.
